The nominating period for the second annual Contact Lens Institute™ (CLI) Culture Awards ends October 1. The program honors eye care professionals who foster a positive contact lens culture, exemplifying behaviors and actions that elevate patient experiences and business success.
Individuals within the U.S. and Canadian eye care community who prescribe or support soft contact lenses are eligible for consideration. Self-nominations are allowed and encouraged. Complete nomination information is available at contactlensinstitute.org/awards.
Nominators simply need to provide a concise response (750 words or less in total) that addresses at least two of the following questions:
How has the nominee enhanced patient outcomes using soft contact lenses?
What initiatives, processes, or projects has the nominee put into place in their practice that enhances a positive culture for recommending soft contact lenses and patient wear?
How does the nominee engage practice staff to take an active advocacy role for healthy, happy soft contact lens wear?
Can you describe a particular nominee-patient interaction that exemplifies how soft contact lenses have changed or improved a patient’s life, and which may inspire colleagues?
To improve the chances of being recognized, nominators may reference positive contact lens behaviors identified in recent See Tomorrow reports, which are available for on-screen reading and/or download from https://www.contactlensinstitute.org/resources/see-tomorrow/.
Nominations must include the name/location/practice name/contact information of the candidate(s), as well as the name/affiliation/contact information for the nominator. Groups are eligible as long as all individuals are named, with a clearly designated leader. Entries must be emailed no later than October 1, 2024, at 11:59 pm ET to cli@contactlensinstitute.org. The submission can be written within the body of the email or attached as a Word or PDF document. Questions may be sent to the same address.
Selection will be at the sole discretion of the CLI Board of Directors. Honorees will be announced by the Contact Lens Institute in November 2024, with ongoing recognition into the following year.
CooperVision’s leadership and commitment to transforming the trajectory of myopia in children will be prominently showcased this week at the prestigious 60th International Myopia Conference (IMC) events in Changsha and Sanya, China. Research findings span the company’s comprehensive range of optical interventions, including MiSight® 1 day soft contact lenses and orthokeratology contact lenses.
“Our dedication to advancing the science and practice of myopia management is on full display at IMC, as teams from CooperVision and our research partners around the globe debut significant new studies.”
Elizabeth Lumb, BSc (Hons) MCOptom, FIACLE, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision
In addition, the company is showcasing multiple category experts through its digital platforms throughout the week, including LinkedIn. Researchers and program team members who have been instrumental in developing, sharing, and promoting invaluable myopia control and management science—work that is changing the lives of children worldwide—reflect on their work and its impact. Learn more at https://www.linkedin.com/company/coopervision.
More than a dozen CooperVision authored and supported papers and posters were accepted to this year’s conference. Highlights include:
Myopia Control with MiSight® 1 day Dual Focus Lenses in Chinese Children (Arumugam B, et al).Interim results from an ongoing, double-masked, multi-center randomized clinical trial in China showed considerable efficacy of MiSight® 1 day in slowing myopia progression. Absolute treatment effects for both axial length and cycloplegic refractive error in children enrolled at ages 7 to 11 were even greater than those observed previously in a majority non-Asian cohort (Chamberlain, et al 2019).[1]
Efficacy of OrthoK in Axial Inhibition: A Comprehensive Retrospective Review of Real-World Patient Population from UC Berkeley Myopia Control Clinic (Jung L, et al).The multi-year retrospective review analyzed records of 424 children fit with Paragon CRT® 100 and CRT Dual Axis® between 2008 to 2023, determining that overnight ortho-k effectively slowed myopia progression as measured by axial elongation. The findings add weight to the clinical usefulness of ortho-k treatments and further confirm that younger children have faster axial growth rates than older children. No cases of microbial keratitis were reported, supporting the efficacy and safety of ortho-k in real-word clinical settings.
Assessment of Performance and Satisfaction with Orthokeratology Lens Among Chinese Wearers and their Parents: A Multicenter Study (Zheng Y, et al). Aier Eye Hospital investigators in 10 cities across China enrolled 588 myopic children ages 8-16 who had worn DreamLite® ortho-k contact lensese bilaterally for at least one year, gaining their subjective feedback and those from their parents. Overall, 98% of wearers and 95% of parents expressed outstanding satisfaction, with excellent comfort and sustained ideal levels of unaided vision throughout the day.
Myopic Defocus Introduced by Dual Focus Myopia Control and Orthokeratology Contact Lenses (Walther G, et al). Indiana University and University of California Berkeley researchers sought to characterize the proportions of myopically defocused light delivered to the retina by MiSight® 1 day contact lenses and Paragon CRT Dual Axis® ortho-k lenses (post-treatment) and their effects on image quality. In ten myopic participants ages 22-30, both treatments—despite different optical designs—introduced approximately 50% myopically defocused light and similar image quality to their foveas.
Additional CooperVision-supported papers and posters include an analysis of myopia control prescribing patterns in the U.S., Australia, and New Zealand, extended efficacy data for SightGlass Vision spectacle lenses with Diffusion Optics Technology™*, and research regarding the potential irradiance hazards of red-light therapy.
The company is once again sponsoring the Chew Sek-Jin Memorial Award Lecture on September 26, which will be delivered this year by myopia researcher, author, and tech entrepreneur Professor Ian Flitcroft, DPhil, FRCOphth.
Multiple studies presented this week at the 2024 International Myopia Conference (IMC) in China significantly reinforce the performance of SightGlass Vision’s Diffusion Optics Technology™ (DOT 0.2) spectacle lenses in slowing myopia progression in children1. The studies affirm positive performance in clinical and real-world settings, demonstrating excellent safety and efficacy, and the lack of a rebound effect.
“The range and depth of evidence being shared at IMC—nine works on contrast theory and DOT lenses as well as an invited guest lecture on contrast theory—should further expand confidence in DOT spectacle lenses, our innovative approach to myopia control,”1,2 said Andrew Sedgwick, CEO of SightGlass Vision.
CHINA and U.S. BASED Clinical Trials
With IMC taking place in Hainan, of particular interest is the six-month data reporting from the CATHAY trial—a two-year, randomized, controlled study across five hospitals in China. Control of Myopia Using Diffusion Optics Technology (DOT) Spectacle Lenses in a Chinese Population: 6-Month Results (Chen Z, et al.) evaluates 186 participants after six months of wear, demonstrating that DOT lenses substantially slows myopia progression as evidenced by minimal change in axial length (AL) and cycloplegic refractive error compared to control group.1
A related analysis—Initial Axial Length Response to Diffusion Optics Technology (DOT) Spectacle Lens Wear (Laughton D, et al.)—shows that AL elongation is halted in almost half of the DOT lens group after six months of wear.3
Following completion of the four-year CYPRESS clinical study in the United States, 54 children were enrolled to assess if the treatment benefit was retained after discontinuing DOT lens wear. Myopia Progression After Cessation of Diffusion Optics Technology (DOT) Spectacle Lenses (Hill J, et al.) presents six-month interim results from the study, suggesting that neither refractive error nor AL increases are faster after DOT lens discontinuation compared to the control2.
“Patterns of Ocular Growth in Young Children Wearing Diffusion Optics Technology (DOT) Spectacle Lenses: A 3-Year Longitudinal Study” shares the particularly positive outcomes for six- and seven-year-old patients in the CYPRESS clinical trial4.
Real World Efficacy in China and Canada CLINICAL SETTINGS
During IMC, SightGlass is making public two real world studies that further validate clinical trial results, using data from patients in China and Canada.
Real-World Effectiveness of Diffusion Optics Technology (DOT) Spectacle Lenses for Myopia Control in Chinese Children (Wang L, McParland M) reviews clinical records from 147 DOT lens patient records. Results show that changes in both refractive error and axial length at six and 12 months from baseline are not significant.5
One-Year Myopia Control Performance of Contrast Modulation Spectacle Lenses Compared to Defocus-Based Spectacle Lenses in a Canadian Practice (Ho K, et al.) analyzes the efficacy of DOT spectacle lenses and peripheral defocus spectacle lenses in 80 Asian-Canadian children ages six to eight at treatment initiation. The study indicates that DOT lenses are more effective in slowing myopia progression (45% better as measured by mSER) compared to the other myopia control lens.6
FOUNDATIONAL RESEARCH
SightGlass Vision’s commitment to building scientific understanding surrounding myopia control will also be evident at the IMC, including posters on Subfoveal Choroidal Thickness Changes After 1-Week of Myopia Control Spectacle Lens Wear (Desiato A, et al.), Contrast Sensitivity Function Differentiates Between Myopia Control Spectacle Lens Designs with Glare and Luminance Manipulations (Wolffsohn J, et al.) and Why Does Near Work Cause Myopia and How Might We Intervene Optically? (Langan R).
Myopia innovator, researcher, and University of Washington Professor Jay Neitz, PhD, has been invited to present on Contrast Theory and its Implications for Novel Myopia Interventions.
SightGlass Vision’s patent-protected technology has made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica. For more information, visit SightGlassVision.com.
References:
Chen et al. Control of Myopia using Diffusion Optics Technology (DOT) spectacle lenses in a Chinese population: 6-month results. To be presented at International Myopia Conference 2024.
Hill et al. Myopia progression after cessation of Diffusion Optics Technology (DOT) spectacle lenses. To be presented at International Myopia Conference 2024.
Laughton et al. Initial axial length reduction in response to Diffusion Optics Technology (DOT) spectacle lens wear. To be presented at International Myopia Conference 2024.
Sheppard et al. Patterns of ocular growth in young children wearing Diffusion Optics Technology (DOT) spectacle lenses: a 3-year longitudinal study. To be presented at International Myopia Conference 2024.
Wang et al. Real-World Effectiveness of Diffusion Optics Technology (DOT) Spectacle Lenses for Myopia Control in Chinese Children. To be presented at International Myopia Conference 2024.
Ho et al. One-Year Myopia Control Performance of Contrast Modulation Spectacle Lenses Compared to Defocus-Based Spectacle Lenses in a Canadian Practice. To be presented at International Myopia Conference 2024.
Myopia Profile is wrapping up Myopia Action Month (MyopiaAction.com) on a high note this week, with impressive engagement numbers highlighting the global enthusiasm of eye care professionals (ECPs) for the initiative’s second year. ECPs have actively participated, drawn to the new, interactive content that Myopia Profile has provided, which will remain available through the end of the month.
“We’re thrilled to see such incredible global interest during Myopia Action Month, with eye care professionals from all corners of the world embracing this important initiative. This year’s participation demonstrates a rising commitment to advancing myopia care and raising awareness about its impact on children’s eye health.”
Dr. Kate Gifford, co-founder, Myopia Profile
Website activity on the program’s dedicated page, MyopiaAction.com, has increased by 16% compared to last year, while social media reach and engagement have surged exponentially. This year, there have been ten times as many posts from ECPs, sponsors, professional associations, educational institutions, and myopia advocacy groups. Notably, only 10% of all social media content was generated by Myopia Profile, highlighting the strong organic interest in the cause.
In this final week of Myopia Action Month, ECPs are encouraged to utilize the evidence-based educational materials, practice tools, and online resources available. These resources are designed to be highly relevant and directly applicable to clinical practice, enhancing both learning and patient care.
“The collaboration with our sponsors has been invaluable in making this effort a success, and we look forward to finishing off the rest of this week with continued enthusiasm and impactful contributions. Together we are making significant strides in addressing myopia and improving outcomes for young patients worldwide,” said Dr. Gifford.
The global initiative aligns with the World Council of Optometry’s advocacy for myopia patient care and is fully supported by Myopia Profile’s visionary sponsors including CooperVision, EssilorLuxottica, HOYA, OCULUS, Johnson & Johnson Vision, Menicon, Ocumetra, Alcon, Topcon Healthcare Europe, SightGlass Vision, Inc., and Visioneering Technologies, Inc.
For more information on Myopia Action Month, including how to access the Online Seminar Series, visit www.myopiaaction.com.
Refocusing its priority on people and celebrating the return of value (and to the values) of human creativity: this is the message MIDO aims to convey with the photos taken by internationally acclaimed photographer Uli Weber.
Registration is now open to visitors planning to attend the exhibition, set to take place at Fiera Milano Rho from February 8 to 10, 2025. And, once again, it is proactively bucking trends with a new communication campaign. With “Refocusing on Humans”,MIDOis emphasizing human creativity and its artisanal capacity to create beauty.
In 2023,when there was much talk about artificial intelligence but still few who were actually using it, MIDO launched the pioneering campaign “Spheres – The Eyewear Universe”, the first in the industry to use AI to create images. Now, while many are applying this technology, MIDO foresees an urgent need that can already be clearly perceived in society – to relaunch human intelligence and its ability to produce new ideas.
With these objectives, for the third consecutive season, creative direction of the campaign was entrusted to Max Galli, in collaboration with Mixer Group. “I imagined an idea of beauty that could grow out of the palpable, material know-how that only the “hearts” and “hands” of the true artisans of eyewear know how to convey,” observed Max Galli. “A visual and conceptual message that diverges from the artificiality of the many intelligences that populate our current reality and that returns humans to the central role.”
Thus arose the idea of a collaboration with a photographic artist, Uli Weber, known internationally for his captivating work in the worlds of fashion, advertising and portraiture. German by birth, Weber mastered his art in Italy, where he developed the ability to create profoundly dramatic images that combine mystery, romanticism and glamour. His photographs are famous in the world of Fine Arts and have been exhibited in museums around the globe.
“I was immediately moved by the creativity expressed by Max Galli in the new campaign for MIDO and, working on the set, with the whole team, was a beautiful experience,” remarked Weber. “In “Refocusing on Humans”, I used bodies to create human sculptures that allude to the world of eyewear, where the hands “frame” the models’ eyes and direct the viewers’ attention, refocusing the glances in an ongoing exchange between spectator and subject. I find the result is a sophisticated but, above all, highly communicative image. I am grateful to Max for having invited me to be part of this project, and to MIDO, that allowed me to do it: we celebrated human beings, but also the expressive power of the eyes, true protagonists of our daily lives.”
Intercultural and sophisticated, “Refocusing on Humans” will appear globally in print and on the internet and will be developed around more than one subject, to be revealed in the coming months.
Starting today visitor registration is open. Last year, more than 40,000 attended from 160 countries. Simply complete the form on the official website by clicking on this link https://www.mido.com/en/entry-pass.
K-774’s retro-inspired look features patterned base acetate and custom lamination on the temple, creating a striking look where colours blend seamlessly.
Delve into the world of night vision technology. From thermal imaging to infrared systems, explore how these innovations improve our ability to see in the dark.
Vision Expo East, organized by co-owners RX and The Vision Council, announces that submissions are now open for the highly anticipated NOW Trend Showcase and Awards at Vision Expo East 2025, taking place in Orlando, FL.
The Association des optométristes du Québec (AOQ) will take the relevant legal measures to challenge the validity of the government’s ministerial order preventing optometrists in the province from exercising a right to which they are entitled: to opt out of the public health plan.
K-774’s retro-inspired look features patterned base acetate and custom lamination on the temple, creating a striking look where colours blend seamlessly.
Delve into the world of night vision technology. From thermal imaging to infrared systems, explore how these innovations improve our ability to see in the dark.
Vision Expo East, organized by co-owners RX and The Vision Council, announces that submissions are now open for the highly anticipated NOW Trend Showcase and Awards at Vision Expo East 2025, taking place in Orlando, FL.
The Association des optométristes du Québec (AOQ) will take the relevant legal measures to challenge the validity of the government’s ministerial order preventing optometrists in the province from exercising a right to which they are entitled: to opt out of the public health plan.
K-774’s retro-inspired look features patterned base acetate and custom lamination on the temple, creating a striking look where colours blend seamlessly.
Delve into the world of night vision technology. From thermal imaging to infrared systems, explore how these innovations improve our ability to see in the dark.
Vision Expo East, organized by co-owners RX and The Vision Council, announces that submissions are now open for the highly anticipated NOW Trend Showcase and Awards at Vision Expo East 2025, taking place in Orlando, FL.
The Association des optométristes du Québec (AOQ) will take the relevant legal measures to challenge the validity of the government’s ministerial order preventing optometrists in the province from exercising a right to which they are entitled: to opt out of the public health plan.
K-774’s retro-inspired look features patterned base acetate and custom lamination on the temple, creating a striking look where colours blend seamlessly.
Delve into the world of night vision technology. From thermal imaging to infrared systems, explore how these innovations improve our ability to see in the dark.
Vision Expo East, organized by co-owners RX and The Vision Council, announces that submissions are now open for the highly anticipated NOW Trend Showcase and Awards at Vision Expo East 2025, taking place in Orlando, FL.
The Association des optométristes du Québec (AOQ) will take the relevant legal measures to challenge the validity of the government’s ministerial order preventing optometrists in the province from exercising a right to which they are entitled: to opt out of the public health plan.
